Two papers on carbamazepine-induced hypersensitivity and its relationship to HLA status

1 Chen P Lin JJ Lu CS Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011; 364:1126–33. doi:10.1056/NEJMoa1009717

2 McCormack M Alfirevic A Bourgeois S HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364:1134–43. doi:10.1056/NEJMoa1013297

3 Roujeau JC Kelly JP Naldi L Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Eng J Med 1995; 333:1600–7. doi:10.1056/NEJM199512143332404

4 Wang L McLeod HL Weinshilboum RM. Genomic medicine: genomics and drug response. N Engl J Med 2011; 364:1144–53. doi: 10.1056/NEJMra1010600

5International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360:753–64. doi:10.1056/NEJMoa0809329. Erratum in N Eng J Med 2009; 361:1613.

6 Paré G Mehta SR Yusuf S , Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Eng J Med 2010; 363:1704– 14. doi:10.1056/NEJMoa1008410

7 Chung WH Hung SI Hong HS Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:486. doi:10.1038/428486a